advertisement
Abstract #15530 Published in IGR 1-3
Effect of brinzolamide and dorzolamide on aqueous humor flow in human eyes
Ingram CJ; Brubaker RFAmerican Journal of Ophthalmology 1999; 128: 292-296
PURPOSE: To measure the relative efficacy of brinzolamide hydrochloride 1% ophthalmic suspension, a new carbonic anhydrase inhibitor, compared with the currently used dorzolamide hydrochloride 2% ophthalmic solution as suppressors of aqueous humor flow in human eyes, and to study the difference of effect during the day and at night. METHODS: A randomized, double-masked, placebo-controlled study of 25 normal human subjects was carried out at Mayo Clinic. The daytime rate of aqueous humor flow was measured every two hours from 8 a.m. to 4 p.m. by means of fluorophotometry. Likewise, the night-time rate of aqueous humor flow was measured every two hours from 12 a.m. to 6 a.m. Intraocular pressure was measured at 4 p.m. and 6 a.m. RESULTS: Brinzolamide reduced aqueous flow by 0.47±0.20 μl per minute (mean±SD) during the day, whereas dorzolamide reduced flow by 0.34±0.20 μl per minute. Brinzolamide reduced aqueous flow by 0.16±0.12 μl per minute during the night, whereas dorzolamide reduced flow by 0.10±0.13 μl per minute. Brinzolamide reduced afternoon intraocular pressure by 1.5±1.1 mmHg, and dorzolamide reduced afternoon intraocular pressure by 1.1±1.0 mmHg. Brinzolamide reduced the morning awakening intraocular pressure by 0.3±1.6 mmHg, and dorzolamide reduced it by 0.8±1.0 mmHg. CONCLUSIONS: These data support the idea that brinzolamide is at least as efficacious as dorzolamide as a suppressor of aqueous humor flow in normal human eyes and that there is probably not a clinically significant difference between the two drugs in this efficacy. Clinicians who prescribe brinzolamide should expect similar ocular hypotensive responses from brinzolamide and dorzolamide.
Dr. C.J. Ingram, Department of Ophthalmology, Mayo Clinic, Rochester, MN 55905; USA
Classification:
11.5.2 Topical (Part of: 11 Medical treatment > 11.5 Carbonic anhydrase inhibitors)
